Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

Summary

The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial effects when combined with paclitaxel in women with platinum resistant ovarian cancer. Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone chemotherapy inclusive of a platinum compound (e.g. carboplatin or cisplatin).

Timeline

Start

2014-09

Primary completion

2016-12-10

Completion

2017-09-30

Drugs

Indications